SG11202103919RA - Methods of treating cns tumors with tesetaxel - Google Patents

Methods of treating cns tumors with tesetaxel

Info

Publication number
SG11202103919RA
SG11202103919RA SG11202103919RA SG11202103919RA SG11202103919RA SG 11202103919R A SG11202103919R A SG 11202103919RA SG 11202103919R A SG11202103919R A SG 11202103919RA SG 11202103919R A SG11202103919R A SG 11202103919RA SG 11202103919R A SG11202103919R A SG 11202103919RA
Authority
SG
Singapore
Prior art keywords
tesetaxel
methods
cns tumors
treating cns
treating
Prior art date
Application number
SG11202103919RA
Inventor
Joyce James
Kevin Tang
Stew Kroll
John G Lemkey
Steven Pfeiffer
Jeff Vacirca
Thomas Wei
Original Assignee
Odonate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odonate Therapeutics Inc filed Critical Odonate Therapeutics Inc
Publication of SG11202103919RA publication Critical patent/SG11202103919RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11202103919RA 2018-10-17 2019-09-05 Methods of treating cns tumors with tesetaxel SG11202103919RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746926P 2018-10-17 2018-10-17
US201962811181P 2019-02-27 2019-02-27
PCT/US2019/049642 WO2020081165A1 (en) 2018-10-17 2019-09-05 Methods of treating cns tumors with tesetaxel

Publications (1)

Publication Number Publication Date
SG11202103919RA true SG11202103919RA (en) 2021-05-28

Family

ID=70283506

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103919RA SG11202103919RA (en) 2018-10-17 2019-09-05 Methods of treating cns tumors with tesetaxel

Country Status (12)

Country Link
US (1) US20210386720A1 (en)
EP (1) EP3866782A4 (en)
JP (1) JP2022505222A (en)
KR (1) KR20210091713A (en)
CN (1) CN113271935A (en)
AU (1) AU2019359755A1 (en)
CA (1) CA3116853A1 (en)
IL (1) IL282389A (en)
MA (1) MA53929A (en)
SG (1) SG11202103919RA (en)
TW (1) TW202027739A (en)
WO (1) WO2020081165A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102405044A (en) * 2009-02-06 2012-04-04 南加利福尼亚大学 Therapeutic compositions comprising monoterpenes
BR112019025164A2 (en) * 2017-06-02 2020-06-16 Odonate Therapeutics, Inc. DOSAGE SCHEME FOR TESETAXEL AND CAPECITABINE

Also Published As

Publication number Publication date
MA53929A (en) 2021-08-25
TW202027739A (en) 2020-08-01
JP2022505222A (en) 2022-01-14
US20210386720A1 (en) 2021-12-16
WO2020081165A1 (en) 2020-04-23
AU2019359755A1 (en) 2021-05-20
IL282389A (en) 2021-06-30
EP3866782A1 (en) 2021-08-25
KR20210091713A (en) 2021-07-22
EP3866782A4 (en) 2022-10-19
CN113271935A (en) 2021-08-17
CA3116853A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
IL269026A (en) Methods of treating tumor
IL275663A (en) Methods of treating cancer
HK1258098A1 (en) Methods of treating cancer
HK1252272A1 (en) Methods of treating cancer using anti-ox40 antibodies
IL263925A (en) Methods of treating ovarian cancer
IL253462B2 (en) Treatment of cancer with anti-lap monoclonal antibodies
IL260444B (en) Anti-her2 combinations for treating tumors
IL264674B1 (en) Anti-siglec-7 antibodies for the treatment of cancer
IL262342A (en) Methods of treating cancer
SG10202012106WA (en) Methods for treating inflammatory conditions of the lungs
IL286297A (en) Methods of treating minimal residual cancer
ZA201808258B (en) Methods of treating pancreatic cancer
HK1251927A1 (en) Novel biomarkers and methods of treating cancer
SG11202010793UA (en) Methods of treating cancer
IL283337A (en) Methods of treating whsc1-overexpressing cancers by inhibiting setd2
IL271934A (en) Methods of treating tumor metastasis
EP3894768C0 (en) Methods of cryo-curing
SG11202005163PA (en) Methods of treating cancer
IL281600A (en) Methods of treating cancer
IL280991A (en) Platelet count-agnostic methods of treating myelofibrosis
IL277981A (en) Methods of treating cancer
IL282389A (en) Methods of treating cns tumors with tesetaxel
IL281284A (en) Methods of treating psoriasis
IL269123A (en) Methods of treating cancer
HK1246851A1 (en) Methods of detecting cancer